» Articles » PMID: 32397616

TFEB Modulates P21/WAF1/CIP1 During the DNA Damage Response

Overview
Journal Cells
Publisher MDPI
Date 2020 May 14
PMID 32397616
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The MiT/TFE family of transcription factors (MITF, TFE3, and TFEB), which control transcriptional programs for autophagy and lysosome biogenesis have emerged as regulators of energy metabolism in cancer. Thus, their activation increases lysosomal catabolic function to sustain cancer cell growth and survival in stress conditions. Here, we found that TFEB depletion dramatically reduces basal expression levels of the cyclin-dependent kinase (CDK) inhibitor p21/WAF1 in various cell types. Conversely, TFEB overexpression increases p21 in a p53-dependent manner. Furthermore, induction of DNA damage using doxorubicin induces TFEB-mediated activation of p21, delays G2/M phase arrest, and promotes cell survival. Pharmacological inhibition of p21, instead, abrogates TFEB-mediated protection during the DNA damage response. Together, our findings uncover a novel and direct role of TFEB in the regulation of p21 expression in both steady-state conditions and during the induction of DNA-damage response (DDR). Our observations might open novel therapeutic strategies to promote cancer cell death by targeting the TFEB-p21 pathway in the presence of genotoxic agents.

Citing Articles

The post-translational regulation of transcription factor EB (TFEB) in health and disease.

Takla M, Keshri S, Rubinsztein D EMBO Rep. 2023; 24(11):e57574.

PMID: 37728021 PMC: 10626434. DOI: 10.15252/embr.202357574.


Transcriptional Dysregulations of Seven Non-Differentially Expressed Genes as Biomarkers of Metastatic Colon Cancer.

Lv X, Li X, Chen S, Zhang G, Li K, Wang Y Genes (Basel). 2023; 14(6).

PMID: 37372321 PMC: 10298541. DOI: 10.3390/genes14061138.


TFEB-dependent lysosome biogenesis is required for senescence.

Curnock R, Yalci K, Palmfeldt J, Jaattela M, Liu B, Carroll B EMBO J. 2023; 42(9):e111241.

PMID: 36970883 PMC: 10152146. DOI: 10.15252/embj.2022111241.


Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancer.

Hany D, Zoetemelk M, Bhattacharya K, Nowak-Sliwinska P, Picard D Cell Mol Life Sci. 2023; 80(3):80.

PMID: 36869202 PMC: 10032341. DOI: 10.1007/s00018-023-04730-x.


TFEB; Beyond Its Role as an Autophagy and Lysosomes Regulator.

Franco-Juarez B, Coronel-Cruz C, Hernandez-Ochoa B, Gomez-Manzo S, Cardenas-Rodriguez N, Arreguin-Espinosa R Cells. 2022; 11(19).

PMID: 36231114 PMC: 9562866. DOI: 10.3390/cells11193153.


References
1.
Georgakilas A, Martin O, Bonner W . p21: A Two-Faced Genome Guardian. Trends Mol Med. 2017; 23(4):310-319. DOI: 10.1016/j.molmed.2017.02.001. View

2.
Weiss R . p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell. 2004; 4(6):425-9. DOI: 10.1016/s1535-6108(03)00308-8. View

3.
Zhang X . A pair of new statistical parameters for quality control in RNA interference high-throughput screening assays. Genomics. 2007; 89(4):552-61. DOI: 10.1016/j.ygeno.2006.12.014. View

4.
Weiss R, Borowsky A, Seligson D, Lin P, Dillard-Telm L, Belldegrun A . p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol. 2006; 177(1):63-8. DOI: 10.1016/j.juro.2006.08.073. View

5.
Hemesath T, Steingrimsson E, McGill G, Hansen M, VAUGHT J, Hodgkinson C . microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev. 1994; 8(22):2770-80. DOI: 10.1101/gad.8.22.2770. View